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Staphylococcus aureus strains (n ⴝ 50) causing complicated skin and skin structure infections produced
various levels of phenol-soluble modulin alpha-type (PSM␣) peptides; some produced more than twice that
produced by the control strain (LAC USA300). TR-700 (oxazolidinone) and clindamycin strongly inhibited
PSM production at one-half the MIC but exhibited weak to modest induction at one-fourth and one-eighth the
MICs, primarily in low producers. Adequate dosing of these agents is emphasized to minimize the potential for
paradoxical induction of virulence.
MIC50/90 values for TR-700 and clindamycin were 0.25/0.375
and 0.125/0.188 g/ml, respectively. Supernatants were harvested after incubation with study drugs at one-half, onefourth, and one-eighth the MICs for PSM quantitation and
global regulator (agrA and RNAIII) expression analysis by
reverse transcription-PCR (RT-PCR) (normalized to expression of gyrB).
Baseline PSM␣ production among 50 clinical isolates varied
from 0.22 to 98.24 g/ml (Fig. 1). Some (14%) isolates produced more than twice the amount of PSM␣1 to -4 peptides
produced by the LAC strain. PSM␣ production did not differ
by methicillin resistance, type of cSSSIs (cellulitis with or without abscess), or size of the abscess (⬎5 or ⱕ5 cm) caused by
these strains.
Clinical strains were grouped by baseline PSM production to
select for representative high, medium, and low producers for
studying the effect of subinhibitory TR-700 and clindamycin on
PSM production. Experiments on growth kinetics with or without drugs were performed on the LAC strain and two clinical
strains (MRSA and MSSA) (Fig. 2). At one-half the MICs of
both drugs, growth was delayed, with a lower final cell count in
LAC but to a lesser degree in the clinical isolates selected,
whereas minimal to no effect on growth was observed at onefourth and one-eighth the MICs for both agents. Measured
PSM␣ concentrations were normalized to the number of CFU
at the time of harvest to account for differences in growth and
cell counts.
Overall, 21 clinical isolates and the LAC strain were tested.
TR-700 at one-half the MIC had a pronounced inhibitory effect on PSM production in a dose-dependent manner, though
the effect varied for all four alpha subtypes (Fig. 3a). PSM␣3
was the most inhibited, in which nearly all isolates tested produced no measurable amounts, while PSM␣4 was the least
inhibited, with production decreasing to a median of 21% of
the baseline value. Interestingly, paradoxical induction of
PSM␣ was observed for TR-700 at one-fourth and one-eighth
the MICs affecting primarily strains with low baseline production of PSM␣3. The highest level of PSM␣3 induced with
TR-700 was 4.6 g/ml from 2.5 g/ml. Similarly, in the LAC
control strain, another low baseline producer of PSM␣3, TR700 at one-half the MIC significantly inhibited PSM produc-

Secreted exotoxins such as toxic shock syndrome toxin 1
(TSST-1), ␣-hemolysin (Hla), and Panton-Valentine leukocidin (PVL) have been shown to contribute in part to the virulence of Staphylococcus aureus (1, 2, 14). The phenol-soluble
modulin alpha-type (PSM␣) peptides (1–4) are one of the most
recently discovered peptides that have been implicated in the
pathogenesis of community-associated methicillin-resistant S.
aureus (CA-MRSA) complicated skin and skin structure infections
(cSSSIs), bacteremia, and pneumonia (2, 16). Like the PVL
toxin, the PSM peptides target primarily neutrophils, leading
to pore formation and inflammatory mediator release. PSM␣3
is the most cytolytic, with 3 to 10 g/ml shown to cause 25 to
60% lysis of human neutrophils (5). PSM␣ peptides are secreted as both nonformylated and formylated forms, with the
latter at a significantly higher quantity and greater cytotoxicity
(16). Previous studies have shown that protein synthesis inhibitors at sub-MICs inhibit the production of Hla, PVL, TSST-1,
and other virulence factors in the laboratory and a few clinical
S. aureus strains (3, 4, 8, 11). We sought to investigate the
effects of subinhibitory concentrations of the protein synthesisinhibiting antibiotics, clindamycin and a second-generation
oxazolidinone, TR-700, on PSM production.
(This study was presented at the 50th Annual Interscience
Conference on Antimicrobial Agents and Chemotherapy [abstract B-709], Boston, MA, 12 to 15 September 2010.)
We examined baseline production of PSM␣1 to -4 in 50
PVL-positive methicillin-susceptible S. aureus (MSSA) and
MRSA clinical isolates causing cSSSIs. Quantitation of formylPSM␣ peptides after 24 h of incubation was performed in
duplicate by liquid chromatography-tandem mass spectrometry (LC-MS-MS). To assess the effect of antibiotics on PSM
production in selected clinical isolates and the LAC (USA300)
control strain, we used a modified CLSI broth macrodilution to
determine the MIC, in which tryptic soy broth was used as the
media and samples were shaken at 250 rpm for 24 h at 37°C.

* Corresponding author. Mailing address: University of Southern
California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA
90089-9121. Phone: (323) 442-1356. Fax: (626) 628-3024. E-mail:
anniew@usc.edu.
䌤
Published ahead of print on 13 June 2011.
4432

VOL. 55, 2011

ANTIVIRULENCE POTENTIAL OF TR-700 AND CLINDAMYCIN

4433

FIG. 1. (a and b) Baseline PSM␣1 to -4 production in clinical isolates and reference strains. (a) Clinical isolates that caused cSSSIs (n ⫽ 50).
Horizontal lines represent median values for each PSM␣ peptide. The interquartile ranges (IQRs) for PSM␣1 to -4 were 16.6 to 35.3, 7.8 to 19.4,
8.5 to 17.5, and 17.5 to 44.6 g/ml, respectively. (b) Staphylococcus aureus control strains. Baseline PSM production of CA, hospital-associated
(HA), and laboratory strains of S. aureus was measured after 24 h of incubation at 37 °C and shaking at 200 rpm. Laboratory strain NRS155 is the
isogenic agr knockout of NRS149, and NRS144 has a partial agr defect.

tion to 30% of the baseline, while one-fourth and one-eighth
the MICs increased PSM production by 40% and 45%, from
3.9 g/ml to 5.43 and 5.63 g/ml, respectively.
Compared to TR-700, clindamycin had a stronger inhibitory
effect on PSM production overall in a subset of the abovementioned isolates (n ⫽ 7) (Fig. 3b). Complete inhibition of
PSM␣1 to -4 was observed at one-half the MIC in all but two
strains. Against PSM␣3, one-fourth the MIC completely inhibited production in 5 of 7 clinical isolates. Like TR-700, PSM
production was weakly induced above the baseline level at
one-fourth and one-eighth the MICs in two clinical isolates and
the LAC strain. Others have documented in the LAC strain
that both clindamycin (at 67% of the MIC) and linezolid (at
10% of the MIC) stimulated PSM production by 3.5 and 1.5
times above the baseline, respectively (6).
Like PVL and Hla, PSMs are under strict control of agrA
and RNAIII of the agr system (9, 10, 16). Others have exam-

ined the effect of antibiotics on RNAIII expression after 8 h
during postexponential growth phase when the agr system
would be maximally expressed (6). We extended the previous
investigation to determine whether the effects persist after
overnight incubation. Expression of agrA and RNAIII appears
to follow the direction of PSM inhibition at sub-MICs of TR700, even after 24 h (Fig. 4). While clindamycin inhibited both
agrA and RNAIII, inhibition was less at one-half the MIC than
one-eighth the MIC, suggesting differential response of these
regulators, or perhaps the inhibitory effect of clindamycin on
agrA is less sustained over time than that of TR-700.
Our study had limitations. First, we chose subinhibitory concentrations of antibiotics that would likely be encountered in
the clinical setting due to improper dosing or other parameters
impacting drug levels at the site of infection. However, growth
was delayed in some strains at one-half the MIC. We normalized measured PSM␣ levels to the number of CFU to account
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FIG. 2. Growth curves of two clinical isolates (MRSA, MSSA) and the LAC (USA300) control strain at sub-MICs of TR-700. Growth curves with
clindamycin were similar (data not shown). Optical densities (ODs) were read every hour for 10 hours, and a final OD reading was taken at 24 hours.

for possible cell count differences, recognizing that this may
not completely account for alteration in growth patterns and,
in turn, PSM production. Second, we did not obtain samples at
earlier time points during growth, which could better characterize responses of global regulators. Finally, the in vitro effects

of subinhibitory TR-700 and clindamycin will need in vivo
confirmation to clarify their clinical relevance (13).
Taken together, our findings indicated that S. aureus strains
causing cSSSIs produced various amounts of PSM␣1 to -4. Our
study results support the antivirulence potential of protein

FIG. 3. (a and b) Effect of subinhibitory concentrations of TR-700 (TR) (a) and clindamycin (CL) (b) on PSM production. Data represent the
medians with IQRs. One-way analysis of variance (ANOVA) with Dunnett’s posttest was used for statistical analysis. Note that an increase in PSM
production from the baseline at one-fourth and one-eighth the MICs of TR-700 and clindamycin occurred primarily in low PSM producers. ***,
P ⬍ 0.0001; *, P ⬍ 0.007.
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FIG. 4. (a and b) Effect of subinhibitory concentrations of TR-700 (a) and clindamycin (b) on expression of agrA and RNAIII. n ⫽ 5 isolates.
Expression is normalized to that of gyrB. *, P ⫽ 0.017.

synthesis-inhibiting antibiotics in decreasing PSM production,
especially at one-half the MIC, consistent with the published
literature on other exotoxins (3, 4, 12, 15). However, it is
notable that these antibiotics can cause paradoxical effects on
PSM production, albeit a weak to moderate induction predominantly in low PSM producers. Our results underscore the
importance of adequate dosing of these agents in order to
minimize the potential for paradoxical induction of virulence.
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